Therapeutic Benefits of Melatonin against COVID-19.
Study Goal
The researchers aimed to evaluate melatonin's potential therapeutic effects against COVID-19, focusing on its anti-inflammatory, antioxidant, and immunomodulatory properties.
Results Summary
Melatonin showed significant improvement in COVID-19 patients by reducing inflammatory cytokines, enhancing immune responses, and potentially protecting against severe disease. The study suggests melatonin could be a promising early treatment option alongside other antivirals.
Population
COVID-19-affected individuals, with noted higher melatonin levels in children possibly offering protection.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | increase | patients' conditions | COVID-19-affected people | - | significant improvement | #1 |
melatonin | increase | against this disease | children | - | provide a protective shield | #2 |
melatonin | neutral | anti-inflammatory, antioxidant, immunomodulator | - | - | works as | #3 |
melatonin | decrease | cytokine release | COVID-19 disease | - | strategically slows down | #4 |
melatonin | increase | overall health | afflicted patients | - | improving | #5 |
melatonin | no change | efficiency of approved vaccines | - | - | does not seem to reduce | #6 |
melatonin | increase | production of inflammatory cytokines and Th1 | - | - | increases | #7 |
melatonin | increase | both humoral and cell-mediated responses | - | - | enhances | #8 |
melatonin | decrease | multiple inflammatory products such as IL-6, IL1β, and tumor necrosis factor α | severe COVID-19 | - | exhibits antiviral activities by suppressing | #9 |
The assumption of the pineal hormone melatonin as a therapeutic use for COVID-19-affected people seems promising. Its intake has shown significant improvement in the patients' conditions. Higher melatonin titers in children may provide a protective shield against this disease. The hormone melatonin works as an anti-inflammatory, antioxidant, immunomodulator, and strategically slows down the cytokine release which is observed in the COVID-19 disease, thereby improving the overall health of afflicted patients. The medical community is expected shortly to use remedial attributes like anti-inflammatory, antioxidant, antivirals, etc., of melatonin in the successful prevention and cure of COVID-19 morbidity. Thus, the administration of melatonin seems auspicious in the cure and prevention of this COVID-19 fatality. Moreover, melatonin does not seem to reduce the efficiency of approved vaccines against the SARS-CoV-2 virus. Melatonin increases the production of inflammatory cytokines and Th1 and enhances both humoral and cell-mediated responses. Through the enhanced humoral immunity, melatonin exhibits antiviral activities by suppressing multiple inflammatory products such as IL-6, IL1β, and tumor necrosis factor α, which are immediately released during lung injury of severe COVID-19. Hence, the novel use of melatonin along with other antivirals as an early treatment option against COVID-19 infection is suggested. Here, we have chalked out the invasion mechanisms and appropriate implications of the latest findings concerned with melatonin against the virus SARS-CoV-2. Nevertheless, within the setting of a clinical intervention, the promising compounds must go through a series of studies before their recommendation. In the clinical field, this is done in a time-ordered sequence, in line with the phase label affixed to proper protocol of trials: phase I-phase II and the final phase III. Nevertheless, while medical recommendations can only be made on the basis of reassuring evidence, there are still three issues worth considering before implementation: representativeness, validity, and lastly generalizability.